Cartesian Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.47) Per Share, HC Wainwright Forecasts (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cartesian Therapeutics in a report released on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.47) for the quarter. HC Wainwright has a “Buy” rating and a $54.00 price target on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.58) EPS.

A number of other brokerages have also recently issued reports on RNAC. SVB Leerink assumed coverage on shares of Cartesian Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $39.00 price objective for the company. Leerink Partnrs restated an “outperform” rating on shares of Cartesian Therapeutics in a report on Tuesday. Finally, Needham & Company LLC began coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 price objective for the company.

Cartesian Therapeutics Trading Up 0.6 %

NASDAQ RNAC opened at $20.72 on Wednesday. Cartesian Therapeutics has a 12 month low of $11.66 and a 12 month high of $42.60. The business’s 50 day moving average price is $19.29.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($0.30) by ($2.10). The company had revenue of $8.27 million during the quarter. Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%.

Insider Buying and Selling

In other Cartesian Therapeutics news, Director Timothy A. Springer purchased 21,612 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $16.20 per share, for a total transaction of $350,114.40. Following the completion of the purchase, the director now directly owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have bought 22,472 shares of company stock valued at $365,981. Corporate insiders own 31.20% of the company’s stock.

Hedge Funds Weigh In On Cartesian Therapeutics

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee acquired a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned 0.98% of Cartesian Therapeutics at the end of the most recent quarter. Institutional investors own 86.95% of the company’s stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.